Edition:
United Kingdom

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.08USD
17 Aug 2018
Change (% chg)

$0.09 (+8.70%)
Prev Close
$0.99
Open
$1.09
Day's High
$1.11
Day's Low
$1.00
Volume
70,984
Avg. Vol
134,450
52-wk High
$3.58
52-wk Low
$0.75

Chart for

About

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide... (more)

Overall

Beta: 2.58
Market Cap(Mil.): $19.23
Shares Outstanding(Mil.): 6.05
Dividend: --
Yield (%): --

Financials

  DARE.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -8.97 -- --
ROI: -126.16 1.78 14.61
ROE: -169.76 3.28 16.33

BRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer

* DARÉ BIOSCIENCE, INC. EXPANDS LEADERSHIP TEAM, APPOINTING JOHN FAIR TO CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients

* DARÉ BIOSCIENCE, INC. ENTERS INTO AGREEMENT TO ACQUIRE PRODUCT TO ADDRESS VULVAR AND VAGINAL ATROPHY IN HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS

07 May 2018

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

25 Apr 2018

BRIEF-Dare Bioscience Says Board Increased Size To 6 Directors

* DARE BIOSCIENCE - ON APRIL 9, BOARD INCREASED SIZE OF BOARD FROM 5 DIRECTORS TO 6 DIRECTORS , ELECTED JESSICA GROSSMAN TO FILL VACANCY - SEC FILING Source: (https://bit.ly/2v7rEnA) Further company coverage:

11 Apr 2018

BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil

* DARÉ BIOSCIENCE, INC. REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

02 Apr 2018

BRIEF-Dare Bioscience Announces Development And Option Agreement With Orbis Biosciences For Long-Acting Injectable Contraceptive

* DARÉ BIOSCIENCE ANNOUNCES EXCLUSIVE DEVELOPMENT AND OPTION AGREEMENT WITH ORBIS BIOSCIENCES FOR LONG-ACTING INJECTABLE CONTRACEPTIVE

12 Mar 2018

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2CC1wzx) Further company coverage:

21 Feb 2018

Earnings vs. Estimates